Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Convertible Debt (2023 - 2025)

Mirum Pharmaceuticals has reported Convertible Debt over the past 3 years, most recently at $309.8 million for Q4 2025.

  • Quarterly results put Convertible Debt at $309.8 million for Q4 2025, up 0.56% from a year ago — trailing twelve months through Dec 2025 was $309.8 million (up 0.56% YoY), and the annual figure for FY2025 was $309.8 million, up 0.56%.
  • Convertible Debt for Q4 2025 was $309.8 million at Mirum Pharmaceuticals, roughly flat from $309.4 million in the prior quarter.
  • Over the last five years, Convertible Debt for MIRM hit a ceiling of $309.8 million in Q4 2025 and a floor of $305.6 million in Q2 2023.
  • Median Convertible Debt over the past 3 years was $307.7 million (2024), compared with a mean of $307.7 million.
  • Biggest five-year swings in Convertible Debt: rose 0.53% in 2024 and later rose 0.56% in 2025.
  • Mirum Pharmaceuticals' Convertible Debt stood at $306.4 million in 2023, then increased by 0.54% to $308.1 million in 2024, then grew by 0.56% to $309.8 million in 2025.
  • The last three reported values for Convertible Debt were $309.8 million (Q4 2025), $309.4 million (Q3 2025), and $308.9 million (Q2 2025) per Business Quant data.